[1] |
Bray F, Ferlay J, Soerjomataram I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6): 394-424.
|
[2] |
Omyla-Staszewska J, Deptala A. Effective therapeutic management of hepatocellular carcinoma-on the basis of a clinical case[J]. Contemp Oncol(Pozn),2012,16(1): 60-63.
|
[3] |
Raoul JL, Kudo M, Finn RS,et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond[J]. Cancer Treat Rev,2018,68: 16-24.
|
[4] |
Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond[J]. World J Gastroenterol,2019,25(7): 789-807.
|
[5] |
Sun WJ, Cabrera R. Systemic treatment of patients with advanced,unresectable hepatocellular carcinoma: emergence of therapies[J]. J Gastrointest Cancer,2018,49(2): 107-115.
|
[6] |
Kudo M, Ueshima K, Torimura T,et al. Randomized,open label,multicenter,phase II trial of transcatheter arterial chemoembolization(TACE)therapy in combination with sorafenib as compared with TACE mechalone in patients with hepatocellular carcinoma: TACTICS trial[J]. JCO,2018,36(15_suppl): 4017.
|
[7] |
Mody K, Abou-Alfa GK. Systemic therapy for advanced hepatocellular carcinoma in an evolving landscape[J]. Curr Treat Options Oncol,2019,20(2): 3.
|
[8] |
Gong XL, Qin SK. Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr,2018,7(6): 466-474.
|
[9] |
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature,2011,473(7347): 298-307.
|
[10] |
Llovet JM, Villanueva A, Lachenmayer A,et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J]. Nat Rev Clin Oncol,2015,12(8): 436.
|
[11] |
Johnson PJ, Qin SK, Park JW,et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study[J]. J Clin Oncol,2013,31(28): 3517-3524.
|
[12] |
Cheng AL, Kang YK, Lin DY,et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial[J]. J Clin Oncol,2013,31(32): 4067-4075.
|
[13] |
Cainap C, Qin SK, Huang WT,et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial[J]. J Clin Oncol,2015,33(2): 172-179.
|
[14] |
Zhu AX, Kudo M, Assenat E,et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial[J]. JAMA,2014,312(1): 57-67.
|
[15] |
Rimassa L, Assenat E, Peck-Radosavljevic M,et al. Second-line tivantinib(ARQ 197)vs placebo in patients(Pts)with MET-high hepatocellular carcinoma(HCC): Results of the METIV-HCC phase III trial[J]. JCO,2017,35(15_suppl): 4000.
|
[16] |
Kudo M, Kang YK, Park JW,et al. Regional differences in efficacy,safety,and biomarkers for second-line axitinib in patients with advanced hepatocellular carcinoma: from a randomized phase II study[J]. Liver Cancer,2018,7(2): 148-164.
|
[17] |
Wilhelm SM, Carter C, Tang LY,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res,2004,64(19): 7099-7109.
|
[18] |
Llovet JM, Ricci S, Mazzaferro V,et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(4): 378-390.
|
[19] |
Cheng AL, Kang YK, Chen ZD,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised,double-blind,placebo-controlled trial[J]. Lancet Oncol,2009,10(1): 25-34.
|
[20] |
Bruix J, Takayama T, Mazzaferro V,et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM):a phase 3,randomised,double-blind,placebo-controlled trial[J]. Lancet Oncol,2015,16(13): 1344-1354.
|
[21] |
Kudo M, Imanaka K, Chida N,et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer,2011,47(14): 2117-2127.
|
[22] |
Lencioni R, Llovet JM, Han GH,et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial[J]. J Hepatol,2016,64(5): 1090-1098.
|
[23] |
Meyer T, Fox R, Ma YT,et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma(TACE 2): a randomised placebo-controlled,double-blind,phase 3 trial[J]. Lancet Gastroenterol Hepatol,2017,2(8): 565-575.
|
[24] |
Yao Q, Zhang HS, Xiong B,et al. Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study[J]. Oncotarget,2017,8(45): 79012-79022.
|
[25] |
Tohyama O, Matsui J, Kodama K,et al. Antitumor activity of lenvatinib(e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models[J]. J Thyroid Res,2014,2014: 638747.
|
[26] |
Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date[J]. J Hepatocell Carcinoma,2019,6: 31-39.
|
[27] |
Ikeda M, Okusaka T, Mitsunaga S,et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res,2016,22(6): 1385-1394.
|
[28] |
Kudo M, Finn RS, Qin SK,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126): 1163-1173.
|
[29] |
Kudo M. Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma[J]. Liver Cancer,2018,7(3): 215-224.
|
[30] |
Kudo M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma[J]. Liver Cancer,2018,7(1): 1-19.
|
[31] |
Jackson R, Psarelli EE, Berhane S,et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: A meta-analysis of randomized phase III trials[J]. J Clin Oncol,2017,35(6): 622-628.
|
[32] |
Wilhelm SM, Dumas J, Adnane L,et al. Regorafenib(BAY 73-4506): a new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J]. Int J Cancer,2011,129(1): 245-255.
|
[33] |
Bruix J, Tak WY, Gasbarrini A,et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre,open-label,phase II safety study[J]. Eur J Cancer,2013,49(16): 3412-3419.
|
[34] |
Bruix J, Qin SK, Merle P,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2017,389(10064): 56-66.
|
[35] |
Bruix J, Merle P, Granito A,et al. Hand-foot skin reaction (HFSR)and overall survival(OS)in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma(HCC)progressing on sorafenib[J]. JCO,2018,36(4_suppl): 412.
|
[36] |
Finn RS, Merle P, Granito A,et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial[J]. J Hepatol,2018,69(2): 353-358.
|
[37] |
Kudo M. Regorafenib as second-line systemic therapy may change the treatment strategy and management paradigm for hepatocellular carcinoma[J]. Liver Cancer,2016,5(4): 235-244.
|
[38] |
Cohn AL, Kelley RK, Yang TS,et al. Activity of cabozantinib (XL184)in hepatocellular carcinoma patients(pts): Results from a phase II randomized discontinuation trial(RDT)[J]. JCO,2012,30(4_suppl): 261.
|
[39] |
Abou-Alfa GK, Meyer T, Cheng AL,et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med,2018,379(1): 54-63.
|
[40] |
Kelley RK, Ryoo BY, Merle P,et al. Outcomes in patients(pts)who had received sorafenib(S)as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib(C)versus placebo (P)in advanced hepatocellular carcinoma(HCC)[J]. JCO,2018,36(15_suppl): 4088.
|
[41] |
Zhu AX, Park JO, Ryoo BY,et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH): a randomised,double-blind,multicentre,phase 3 trial[J]. Lancet Oncol,2015,16(7): 859-870.
|
[42] |
Zhu AX, Kang YK, Yen CJ,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2): a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet Oncol,2019,20(2): 282-296.
|
[43] |
Kudo M. Ramucirumab as second-line systemic therapy in hepatocellular carcinoma[J]. Liver Cancer,2018,7(4): 305-311.
|
[44] |
Zhu J, Yin TL, Xu Y,et al. Therapeutics for advanced hepatocellular carcinoma: Recent advances,current dilemma,and future directions[J]. J Cell Physiol,2019-1-15. [Epub ahead of print]
|
[45] |
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application[J]. Int Immunol,2007,19(7): 813-824.
|
[46] |
Nivolumab approved for liver cancer[J]. Cancer Discov,2017,7(11): OF3.
|
[47] |
Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation[J]. J Exp Med,1995,182(2): 459-465.
|
[48] |
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade[J]. Science,1996,271(5256): 1734-1736.
|
[49] |
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nat Rev Cancer,2019,19(3): 133-150.
|
[50] |
Forde PM, Chaft JE, Smith KN,et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med,2018,378(21): 1976-1986.
|
[51] |
Lu X, Horner JW, Paul E,et al. Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer[J]. Nature,2017,545(7652): 116.
|
[52] |
Turajlic S, Larkin J. Immunotherapy for melanoma metastatic to the brain[J]. N Engl J Med,2018,379(8): 789-790.
|
[53] |
Obeid JM, Kunk PR, Zaydfudim VM,et al. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?[J]. Cancer Immunol Immunother,2018,67(2): 161-174.
|
[54] |
Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update[J]. Liver Cancer,2016,6(1): 1-12.
|
[55] |
Topalian SL, Hodi FS, Brahmer JR,et al. Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med,2012,366(26): 2443-2454.
|
[56] |
El-Khoueiry AB, Sangro B, Yau TC,et al. Phase I/II safety and antitumor activity of nivolumab(nivo)in patients(pts)with advanced hepatocellular carcinoma(HCC): Interim analysis of the CheckMate-040 dose escalation study[J]. JCO,2016,34(15_suppl): 4012.
|
[57] |
El-Khoueiry AB, Sangro B, Yau T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet,2017,389(10088): 2492-2502.
|
[58] |
Sangro B, Park JW, Dela Cruz CM,et al. A randomized,multicenter,phase 3 study of nivolumab vs sorafenib as first-line treatment in patients(pts)with advanced hepatocellular carcinoma (HCC): CheckMate-459[J]. JCO,2016,34(15_suppl): TPS4147.
|
[59] |
Finkelmeier F, Czauderna C, Perkhofer L,et al. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers[J]. J Cancer Res Clin Oncol,2019,145(1): 253-259.
|
[60] |
Zhu AX, Finn RS, Edeline J,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224): a non-randomised,open-label phase 2 trial[J]. Lancet Oncol,2018,19(7): 940-952.
|
[61] |
Finn RS, Chan SL, Zhu AX,et al. KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma[J]. JCO,2017,35(4_suppl): TPS503.
|
[62] |
Gavin MA, Rasmussen JP, Fontenot JD,et al. Foxp3-dependent programme of regulatory T-cell differentiation[J]. Nature,2007,445(7129): 771-775.
|
[63] |
Wu YQ, Borde M, Heissmeyer V,et al. FOXP3 controls regulatory T cell function through cooperation with NFAT[J]. Cell,2006,126(2): 375-387.
|
[64] |
Sangro B, Gomez-Martin C, de la Mata M,et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol,2013,59(1): 81-88.
|
[65] |
Duffy AG, Ulahannan SV, Makorova-Rusher O,et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol,2017,66(3): 545-551.
|
[66] |
Melero I, Hervas-Stubbs S, Glennie M,et al. Immunostimulatory monoclonal antibodies for cancer therapy[J]. Nat Rev Cancer,2007,7(2): 95-106.
|
[67] |
Berger R, Rotem-Yehudar R, Slama G,et al. Phase I safety and pharmacokinetic study of CT-011,a humanized antibody interacting with PD-1,in patients with advanced hematologic malignancies[J]. Clin Cancer Res,2008,14(10): 3044-3051.
|
[68] |
Motzer RJ, Penkov K, Haanen J,et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med,2019,380(12): 1103-1115.
|
[69] |
Choueiri TK, Larkin J, Oya M,et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma(JAVELIN Renal 100): an open-label,dose-finding and dose-expansion,phase 1b trial[J]. Lancet Oncol,2018,19(4): 451-460.
|
[70] |
McDermott DF, Huseni MA, Atkins MB,et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma[J]. Nat Med,2018,24(6): 749-757.
|
[71] |
Wallin JJ, Bendell JC, Funke R,et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma[J]. Nat Commun,2016,7: 12624.
|
[72] |
Lee KH, Hsu CH, Lee MS,et al. Atezolizumab plus bevacizumab in hepatocellular carcinoma(HCC): Safety and clinical activity results from a phase Ib study[J]. Ann Oncol,2018,29: 47.
|
[73] |
Pishvaian MJ, Lee MS, Ryoo BY,et al. LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma(HCC)[J]. Ann Oncol,2018,29(suppl_8): 2.
|
[74] |
Kelley RK, Abou-Alfa GK, Bendell JC,et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma(HCC): Phase I safety and efficacy analyses[J]. JCO,2017,35(15_suppl): 4073.
|
[75] |
Dawkins J, Webster RM. The hepatocellular carcinoma market[J]. Nat Rev Drug Discov,2019,18(1): 13-14.
|
[76] |
Taylor M, Dutcus CE, Schmidt E,et al. A phase 1b trial of lenvatinib(LEN)plus pembrolizumab(PEM)in patients with selected solid tumors[J]. Ann Oncol,2016,27(suppl_6): 1.
|
[77] |
Ikeda M, Sung MW, Kudo M,et al. A phase 1b trial of lenvatinib (LEN)plus pembrolizumab(PEM)in patients(pts)with unresectable hepatocellular carcinoma(uHCC)[J]. JCO,2018,36(15_suppl): 4076.
|
[78] |
Xu JM, Zhang Y, Jia R,et al. Anti-programmed death-1 antibody SHR-1210(S)combined with apatinib(A)for advanced hepatocellular carcinoma(HCC),gastric cancer(GC)or esophagogastric junction(EGJ)cancer refractory to standard therapy: A phase 1 trial[J]. JCO,2018,36(15_suppl): 4075.
|
[79] |
Kudo M. Combination cancer immunotherapy with molecular targeted agents/anti-CTLA-4 antibody for hepatocellular carcinoma[J]. Liver Cancer,2019,8(1): 1-11.
|